-
St Johns Wort and Drug Interactions; Serum Potassium and Stroke Risk Among Hypertensive Adults; Skin Cancer Prevention and Detection Practices Among Siblings of Patients with Melanoma
-
A high saturated-fat and no-starch diet resulted in modest weight loss without negative effects on serum lipid levels; weight loss can be continued for up to a year with such a diet.
-
A consensus panel updates recent understanding about the causes and treatment in common neuropathic pain problems.
-
The study found that high-intensity warfarin therapy was not necessary for the prevention of recurrent thrombosis in the APA syndrome.
-
A majority of gastric fundic polyps are benign. Their presence in unscreened individuals older than 50 might warrant colonoscopy.
-
The FDA has approved tadalafil, the third phosphodiesterase type 5 inhibitor (PDE5) for the treatment of erectile dysfunction.
-
Two injectable biologic therapies, etanercept and efalizumab, have been shown to be highly effective in treating psoriasis. Etanercept has been used in rheumatoid arthritis since 1998, and efalizumab is a new agent in phase III trials. Psoriasis is a debilitating autoimmune illness, and these new therapies, while expensive, will be a welcome addition for patients suffering from a severe form of this disease.
-
Sulfonamide Antibiotics and Sulfonamide Nonantibiotics; Autoantibodies Before Onset of SLE; Prevention of VTE with Ximelagatran
-
The FDA has approved Pfizer's eplerenone (Inspra) for the treatment of congestive heart failure (CHF) in patients who have sustained a myocardial infarction.
-
The following is a late-breaking trial of the American Heart Association Annual Scientific Sessions held last month in Orlando, Fla. The REVERSAL trial is covered in the pages of Internal Medicine Alert because of the abundant coverage of this issue in the lay press, as well as possible questions your patients may ask regarding this subject.
